This inventor holds 122 USPTO granted patents and 13 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Cancer Immunotherapy (CPC class 436548). Top assignees: Ludwig Institute for Cancer Research Limited, Sloan-Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center. Active years: 1985-2019.
Inventors with similar research interests:
Company Filing History:
56 out of 530 
32 out of 518 
23 out of 618 
Years Active: 1985-2019
Areas of Expertise:
Title: Lloyd J Old: Pioneering Cancer Therapies through Innovative Patents
Introduction:
Lloyd J Old, a renowned researcher and inventor based in New York, NY, has made significant contributions to the field of cancer therapy through his groundbreaking innovations and patented inventions. With an impressive record of 121 patents to his name, Old has been at the forefront of developing novel treatments targeting specific membrane transporters and epitopes that hold promise in cancer therapy. This article delves into Old's latest patents, highlights from his career, notable collaborations, and his impactful contributions to the field of cancer research.
Latest Patents:
Old's latest patents revolve around the membrane transporter NaPi2b (SLC34A2) as a target for therapy, particularly in the realm of cancer immunotherapy. His inventions include the identification of an ovarian cancer epitope using the monoclonal antibody MX35 and the subsequent development of antibodies, both humanized and chimeric, specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s). These antibodies possess anti-tumor and anti-cancer activity and have demonstrated potential in stimulating an immunological response against cancer cells. Old's patents also encompass methods for generating immune responses, treatment of tumors, and cancer screening assays.
Career Highlights:
Throughout his illustrious career, Old has held significant positions at esteemed institutions dedicated to cancer research. He notably worked at the Ludwig Institute for Cancer Research Limited, where he played a pivotal role in advancing innovative approaches for cancer treatment. Additionally, Old's contributions at the Sloan-Kettering Institute for Cancer Research have been instrumental in furthering our understanding of cancer biology and developing promising therapies.
Collaborations:
Old's accomplishments would not have been possible without his collaborations with esteemed colleagues in the field. Notably, he has worked closely with Yao-tseng Chen, a fellow researcher known for his contributions to cancer therapeutics. Their collaboration has resulted in the development of state-of-the-art antibody-based therapies with great potential in cancer treatment. Another notable collaborator is Elisabeth Stockert, a respected figure in the field, whose expertise and insights have enriched Old's research endeavors.
Conclusion:
Lloyd J Old's extensive portfolio of patents, coupled with his remarkable career in cancer research, solidify his position as a trailblazer in the field of cancer therapy. His innovative approach, targeting membrane transporters and epitopes, showcases the potential of immunotherapy for cancer treatment. Through collaborations with esteemed researchers and institutions, Old has fostered advancements that hold great promise for patients battling cancer. His contributions continue to shape the landscape of innovative treatments, offering hope to individuals affected by this devastating disease.